Transferring Early-stage Drug, Biologics Research From West To East Will Speed Up Over Next Five Years
This article was originally published in PharmAsia News
Executive Summary
BEIJING - A survey of leaders of U.S. pharmaceutical and biotech firms conducted by Citi Investment Research and Analysis indicates that outsourcing early-stage research to scientists at contract research organizations in China and India could see high-speed expansion over the next five years
You may also be interested in...
Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool
BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership
Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool
BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership
WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives
BEIJING - The chief executive officer of Shanghai-headquartered WuXi PharmaTech, Ge Li, said that a planned merger with Massachusetts-based contract research organization Charles River could help spark a "revolution" in early-stage drug research in China